MedTrace Logo

A Study of HY209 in Healthy Male Volunteers for Sepsis

NCT04255979 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-11-30

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled single dosing, dose escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HY209 after intravenous administration in healthy male volunteers

Conditions

Interventions

DRUG

HY209

6 Subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.

Sponsors & Collaborators

  • Shaperon

    lead INDUSTRY

Principal Investigators

  • In-jin Jang · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-05
Primary Completion
2020-06-12
Completion
2020-06-12

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04255979 on ClinicalTrials.gov